Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Types (Indirect ELISA, Sandwich ELISA, Competitive ELISA), By Application (Food And Beverage, Vaccine Development, Immunology, Diagnosis, Drug Monitoring, Others), By End Users (Pharmaceutical Industries, Hospitals And Clinics, Diagnostic Centres, Others), And By Geography - Forecasts From 2022 To 2027

  • Published : Nov 2022
  • Report Code : KSI061611695
  • Pages : 135

The global Enzyme-Linked Immunosorbent Assay (ELISA) market is projected to grow at a CAGR of 5.54%, increasing from US$7.854 billion in 2020 to US$11.458 billion in 2027.

ELISA (enzyme-linked immunosorbent assay) or enzyme immunoassay (EIA) is a plate-based assay technique designed for detecting and quantifying substances such as peptides, proteins, antibodies, and hormones. ELISA is often used as a screening tool before further in-depth tests are ordered. Reactants of the ELISA are immobilized to the microplate surface making it easy to separate bound from non-bound material during the assay making it a powerful tool for measuring specific analytes within a crude preparation. The common diagnostic applications of ELISA are HIV infection, pregnancy tests, detection of proteins, etc. The ELISA market is expected to show robust growth during the forecast period. The growth may be attributed to the rising incidence of infectious and chronic diseases which require ELISA as a cost-effective diagnostic tool. However, stringent regulatory requirements, as well as unfavourable reimbursement policies pertaining to ELISA, might hamper the growth of the market during the given time frame.


One of the key drivers fueling the market's expansion is the rising prevalence of infectious diseases like HIV, Hepatitis, malaria, dengue, and influenza, among other ailments. At the end of 2021, the WHO estimated that there were 38.4 million HIV-positive individuals worldwide, with more than two-thirds of them living in Africa. The WHO also claimed that dengue fever was among the top ten health threats facing the world. Over the past 50 years, dengue incidences have increased by about 3000% worldwide. WHO also estimated that more than 296 million individuals worldwide have hepatitis B infection as of 2019. The demand for diagnosis is anticipated to rise as a result of the rising occurrence of infectious diseases. The market is anticipated to expand as a result of the rising use of cutting-edge diagnostic techniques for screening these disorders, such as enzyme-linked immunosorbent tests.

Additionally, the growing geriatric population, which is globally at risk of contracting illnesses and chronic diseases and requires routine diagnosis, is anticipated to fuel market expansion. In comparison to younger individuals, potentially dangerous illnesses are more likely in elderly patients, according to the NCBI (National Center for Biotechnology Information), which published this information in 2021. Thus, it is anticipated that these factors will considerably raise the market's growth by boosting demand for enzyme-linked immunosorbent assays.

Disease diagnosis segment holds a substantial share of the market

Due to the growing use of enzyme-linked immunosorbent assay tests for the diagnosis of specific antigens, a sizable share of the disease diagnosis market has been predicted. Non-communicable illnesses were estimated by the WHO to cause around 41 million deaths each year, equivalent to 71% of all deaths worldwide, in 2022. Due to these occurrences, there is now a greater need for efficient diagnostic techniques like ELISA for prompt detection to minimize death occurrences. Additionally, according to the Global Cancer Observatory, there were approximately 19.3 million new cases of cancer and nearly 10.0 million cancer deaths worldwide in 2020. As ELISA is a useful instrument for assessing antigens, the rise in cancer incidence around the world is driving up demand for it. Additionally, the Enzyme-Linked Immunosorbent Assay can be used to find both breast cancer antigens and prostate cancer antigens, according to a 2020 Nature Scientific study. Such accurate antigen screening and cost-effective diagnosis are anticipated to boost ELISA demand and drive the market's expansion during the analyzed period.

North America is Expected to Hold a Significant Share in the Market

Because of the rapid development of technological breakthroughs in screening instruments like ELISA, the US is likely to dominate the global market. The increasing incidences of multiple infectious and chronic diseases in this demography are contributing to the strong growth of the demand for Enzyme-Linked Immunosorbent Assay. For instance, the CDC (Centre for Ailment Control and Prevention) reported in 2022 that over 60% of Americans had at least one chronic disease, such as cancer, cardiovascular disease, or stroke. The market in this region is anticipated to grow as a result of rising R&D expenditures as well as numerous funding initiatives for diagnostics. Listed firms on the biotechnology index expanded their R&D spending by about 16% on average in 2020 to USD 284.25 million in the US, based on the Binder Dijker Otte USA Reports from 2020. Additionally, in 2021, the Department of Health and Human Services said that it would deploy USD 650 million from the American rescue plan to increase production capabilities for swift, high-quality diagnostic tests. Therefore, it is projected that all of these aspects will support the North American regional market well over the predicted period.

COVID-19 Insights

Worldwide demand for immunoassays like enzyme-linked immunosorbent tests surged as a result of COVID-19. The main cause of this was the rise in disease rates, which prompted a greater demand for accurate diagnosis. In 2020, the NCBI Journal reported that ELISA can accurately detect SARS-CoV-2. As a result, the market's expansion was fueled by a rise in the need for accurate diagnoses at a reasonable cost.

Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Scope:


Report Metric Details
 Market Size Value in 2020  US$7.854 billion
 Market Size Value in 2027  US$11.458 billion
 Growth Rate  CAGR of 5.54% from 2020 to 2027
 Base Year  2020
 Forecast Period  2022–2027
 Forecast Unit (Value)  USD Billion
 Segments Covered  Type, Application, End Users, And Geography
 Regions Covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies Covered Pestka Biomedical Laboratories, Inc., Diaclone SAS, Thermo Fisher Scientific Inc., Azure Biosystems Inc., R&D Systems, Inc., RayBiotech, Inc., Elabscience, BioLegend, Inc., Randox Toxicology, STEMCELL Technologies Inc., Genway Biotech, Inc.
 Customization Scope  Free report customization with purchase



  • By Types
    • Indirect ELISA
    • Sandwich ELISA
    • Competitive ELISA
  • By Application
    • Food and Beverage
    • Vaccine Development
    • Immunology
    • Diagnosis
    • Drug Monitoring
    • Others 
  • By End Users
    • Pharmaceutical Industries
    • Hospitals and Clinics
    • Diagnostic Centres
    • Others 
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • UK
      • Germany
      • France
      • Italy
      • Spain
      • Others
    • Middle East and Africa (MEA)
      • Saudi Arabia
      • UAE
      • Isreal
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
      • Indonesia
      • Thailand
      • Taiwan
      • Others

Frequently Asked Questions (FAQs)

The enzyme-linked immunosorbent assay market is projected to reach a total market size of US$11.458 billion by 2027.
Enzyme-Linked Immunosorbent Assay (ELISA) Market was valued at US$7.854 billion in 2020.
The global enzyme-linked immunosorbent assay market is projected to grow at a CAGR of 5.54% during the forecast period.
North America is expected to hold a significant share of the enzyme-linked immunosorbent assay market due to the rapid adoption of technological advancements in diagnostic tools like ELISA.
The growing incidence of infectious diseases such as HIV, Hepatitis, malaria, Dengue, and influenza, among various other infections is one of the major factors driving the enzyme-linked immunosorbent assay market growth.


1.1. Market Overview

1.2. Covid-19 Scenario

1.3. Market Definition

1.4. Market Segmentation



2.1. Research Data

2.2. Assumptions



3.1. Research Highlights



4.1. Market Driver

4.2. Market Restraints

4.3. Porters Five Forces Analysis

4.3.1. Bargaining Power of End-Users

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis



5.1. Introduction 

5.2. Indirect ELISA

5.3. Sandwich ELISA

5.4. Competitive ELISA



6.1. Introduction 

6.2. Food and Beverage

6.3. Vaccine Development

6.4. Immunology

6.5. Diagnosis

6.6. Drug Monitoring

6.7. Others 



7.1. Introduction 

7.2. Pharmaceutical Industries

7.3. Hospitals and Clinics

7.4. Diagnostic Centres

7.5. Others 



8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. UK

8.4.2. Germany

8.4.3. France

8.4.4. Italy

8.4.5. Spain

8.4.6. Others

8.5. Middle East and Africa (MEA)

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Isreal

8.5.4. Others

8.6. Asia Pacific 

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. Australia

8.6.5. South Korea

8.6.6. Indonesia

8.6.7. Thailand 

8.6.8. Taiwan

8.6.9. Others



9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix



10.1. Pestka Biomedical Laboratories, Inc.

10.2. Diaclone SAS

10.3. Thermo Fisher Scientific Inc. 

10.4. Azure Biosystems Inc. 

10.5. R&D Systems, Inc.

10.6. RayBiotech, Inc.

10.7. Elabscience

10.8. BioLegend, Inc.

10.9. Randox Toxicology

10.10. STEMCELL Technologies Inc.

10.11. Genway Biotech, Inc.

Pestka Biomedical Laboratories, Inc.

Diaclone SAS

Thermo Fisher Scientific Inc.

Azure Biosystems Inc.

R&D Systems, Inc.

RayBiotech, Inc.


BioLegend, Inc.

Randox Toxicology

STEMCELL Technologies Inc.

Genway Biotech, Inc.